Published 13 February 2021
(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a prostate cancer session Best of Journals with Dr. Keyan Salari providing the surgical perspective. Dr. Salari selected two studies assessing active surveillance in Black men with low-risk prostate cancer, and one study assessing the timing of radiation therapy after radical prostatectomy.
The first paper was by Deka et al. “Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer with Active Surveillance” published in the
Journal of the American Medical Association (JAMA).
1 Dr. Salari notes that there has been lower uptake of active surveillance among Black men, potentially leading to an increased burden of treatment-related side-effects. As we learn more about active surveillance, it is important to ensure that all members of the population are able to take advantage of the b
Published 13 February 2021
(UroToday.com) The ASCO GU 2021 Genitourinary Cancers Symposium annual meeting included an invited discussion from Dr. Arlene Siefker-Radtke discussing “Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma” and “EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.”
Dr. Siefker-Radtke notes that we now have level 1 evidence with overall survival benefit for enfortumab vedotin in the 3
rd line for metastatic urothelial carcinoma. EV-301 (NCT03474107) is a global, open-label phase III study of enfortumab vedotin versus chemotherapy conducted in patients with locally advanced or metastatic urothelial carcinoma who had received prior platinum-containing chemotherapy and had disease progression during or after PD-1/L1 in
ASCO GU 2021 Genitourinary Cancers Symposium, Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST), Testicular Seminoma.
SHARE
ASCO GU 2021: Alignment and Discordances in Perceptions and Experiences of Shared Decision Making Among Bladder Cancer Patients and Their Care Team
Published 13 February 2021
(UroToday.com) Shared decision-making regarding cancer treatment is critical. In previous PRIME educational programs involving patients with bladder cancer and their care teams, effective shared decision-making was found to be integral to the development of treatment plans that reflected patient preferences and treatment goals. However, oncology care teams face complex barriers that impede their ability to personalize bladder cancer therapy for each patient. PRIME conducted a Collaborative Learning Program in five US healthcare systems to support communication and shared decision-making between patients with bladder cancer and their urology/medical oncology teams to improve outcomes and quality of life for these patients. At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Ca
ESOU 2021: ESUR Lecture: Genetic Testing for Prostate Cancer: When and How?
(UroToday.com) At the 2021 European Association of Urology (EAU) Section of Oncological Urology (ESOU) Virtual Annual Meeting, the EAU Section of Urological Research (ESUR) lecture was provided by Dr. Karen Knudsen discussing when and how to provide genetic testing for prostate cancer. Dr. Knudsen pointed out that there is an extraordinary burden of prostate cancer in the US, ranked as #1 for males in estimated new cases and #2 in estimated cancer-related deaths. Germline testing is revolutionizing care, with 12-17% of metastatic patients having germline mutations and 5-7% of early-stage patients having germline mutations. As such, germline testing is impacting precision medicine and tailored screening approaches, which also has an impact on families for hereditary cancer risk.